Breast Cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: A population-based cohort study

Journal of Clinical Oncology

Volumn 34, Issue 19, 2016, Pages 2239-2246

  Thavendiranathan, Paaladinesh ^a   Abdel Qadir, Husam ^b   Fischer, Hadas D ^b   Camacho, Ximena ^b   Amir, Eitan ^b   Austin, Peter C ^b   Lee, Douglas S ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL PRACTICE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART DISEASE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BREAST NEOPLASMS; CHEMICALLY INDUCED; HEART FAILURE; INCIDENCE; MIDDLE AGED; PATHOPHYSIOLOGY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOTOXICITY; COHORT STUDIES; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84975457567     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.1505     Document Type: Article

References (36)

1. International Agency for Research on Cancer and Cancer Research UK: World Cancer Fact Sheet. Geneva, Switzerland, World Health Organization, 2014
2. Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65:87-108, 2015
3. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005
4. Bowles EJ, Wellman R, Feigelson HS, et al: Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 104:1293-1305, 2012
5. Doyle JJ, Neugut AI, Jacobson JS, et al: Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 23:8597-8605, 2005
6. Du XL, Xia R, Burau K, et al: Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005. Med Oncol 28:S80-S90, 2011 (suppl 1)
7. Pinder MC, Duan Z, Goodwin JS, et al: Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808-3815, 2007
8. National Center for Health Statistics, Centers for Disease Control and Prevention: US Mortality Files: SEER Cancer Statistics Review 1975-2008. Bethesda, MD, National Cancer Institute, 2011
9. Jatoi I, Chen BE, Anderson WF, et al: Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 25:1683-1690, 2007
10. Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol 25:3859-3865, 2007
11. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
12. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
13. Yoon GJ, Telli ML, Kao DP, et al: Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 56:1644-1650, 2010
14. Lu CY, Srasuebkul P, Drew AK, et al: Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function? Breast 22:482-487, 2013
15. Subar M, Lin W, Chen W, et al: Lack of uniformity in cardiac assessment during trastuzumab therapy. Breast J 17:383-390, 2011
16. Chavez-MacGregor M, Niu J, Zhang N, et al: Cardiac monitoring during adjuvant trastuzumabbased chemotherapy among older patients with breast cancer. J Clin Oncol 33:2176-2183, 2015
17. Robles SC, Marrett LD, Clarke EA, et al: An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol 41:495-501, 1988
18. Hux JE, Ivis F, Flintoft V, et al: Diabetes in Ontario: Determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25:512-516, 2002
19. Schultz SE, Rothwell DM, Chen Z, et al: Identifying cases of congestive heart failure from administrative data: A validation study using primary care patient records. Chronic Dis Inj Can 33:160-166, 2013
20. Tu K, Campbell NR, Chen ZL, et al: Accuracy of administrative databases in identifying patients with hypertension. Open Med 1:e18-e26, 2007
21. Tu K, Mitiku T, Lee DS, et al: Validation of physician billing and hospitalization data to identify patients with ischemic heart disease using data from the Electronic Medical Record Administrative data Linked Database (EMRALD). Can J Cardiol 26: e225-e228, 2010
22. Vermeulen MJ, Tu JV, Schull MJ: ICD-10 adaptations of the Ontario acute myocardial infarction mortality prediction rules performed as well as the original versions. J Clin Epidemiol 60:971-974, 2007
23. Tu K, Chen Z, Lipscombe LL: Prevalence and incidence of hypertension from 1995 to 2005: A population-based study. CMAJ 178:1429-1435, 2008
24. Chan W, Yun L, Austic PC, et al: Impact of socio-economic status on breast cancer screening in women with diabetes: A population-based study. Diabet Med 31:806-812, 2014
25. Lau B, Cole SR, Gange SJ: Competing risk regression models for epidemiologic data. Am J Epidemiol 170:244-256, 2009
26. Putter H, Fiocco M, Geskus RB: Tutorial in biostatistics: Competing risks and multi-state models. Stat Med 26:2389-2430, 2007
27. Rothman KJ: Measuring disease occurrence and causal effects, in Rothman KJ (ed): Epidemiology: An Introduction (ed 2). New York, NY, Oxford University Press, 2012, pp 38-68
28. Canadian Cancer Society's Advisory Committee on Cancer Statistics: Canadian Cancer Statistics 2007. Toronto, Ontario, Canada, Canadian Cancer Society, 2007
29. Romond EH, Jeong JH, Rastogi P, et al: Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792-3799, 2012
30. Chen T, Xu T, Li Y, et al: Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis. Cancer Treat Rev 37: 312-320, 2011
31. Chavez-MacGregor M, Zhang N, Buchholz TA, et al: Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31:4222-4228, 2013
32. Chen J, Long JB, Hurria A, et al: Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60:2504-2512, 2012
33. Du XL, Xia R, Liu CC, et al: Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer 115:5296-5308, 2009
34. Birman-Deych E, Waterman AD, Yan Y, et al: Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 43: 480-485, 2005
35. Lee DS, Donovan L, Austin PC, et al: Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care 43:182-188, 2005
36. Cardinale D, Colombo A, Bacchiani G, et al: Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981-1988, 2015